CTRI/2020/05/025063已完成2 期
A pre experimental study to assess the impact of culturally appropriate and theoretically driven Nurse Led Counselling Intervention given to parents of children with Cerebral Visual Impairment (CVI) on adherence to eye activities attending Advanced Eye Centre at PGIMER, Chandigarh,2019-21
ational Institute of Nursing Education PGIMER SEC Chandigarh0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Children with CVI between the age of 3 month-12 years registered since 2018 onwards in AEC OPD at PGIMER, Chandigarh after August 2020 onwards.
排除标准
- •Children with other Congenital anomalies along with CVI, who require immediate medical care.
研究者
相似试验
招募中
2 期
A prospective study to investigate the effect of CBM558 combined with pembrolizumab on gut microbiota and prognosis in patients with advanced urothelial carcinoma.JPRN-jRCTs031220689Taguchi Satoru30
进行中（未招募）
不适用
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-005710-11-DEOXXON Pharma AG75
进行中（未招募）
不适用
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-005710-11-CZOXXON Pharma AG75
进行中（未招募）
不适用
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-005710-11-HUOXXON Pharma AG75
进行中（未招募）
不适用
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriaEUCTR2011-005710-11-PLOXXON Pharma AG75